Amnion derived adherent cells

• US 8,367,409 B2
• Filed: 11/19/2009
• Issued: 02/05/2013
• Est. Priority Date: 11/19/2008
• Status: Active Grant

• Current Assignee: Celularity, Inc.
• Original Assignee: Anthrogenesis Corporation (Bristol-Myers Squibb Company)
• Inventors: Abbot, Stewart, Edinger, James W., Francki, Aleksandar, Kaplunovsky, Aleksandr, Jankovic, Vladimir, Labazzo, Kristen, Law, Eric, Padliya, Neerav D., Paredes, Jennifer, Wang, Jia-Lun
• Primary Examiner(s): Ton, Thaian N
• Application Number:
  US12/622,352
• Publication Number:
  US 20100124569A1
• Time in Patent Office: 1,174 Days
• Field of Search: 435/366, 435/373
• US Class Current: 435/366
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/50 Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12N 5/0605 Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly

Abstract

Provided herein are novel angiogenic cells from amnion, referred to as amnion derived adherent cells, and populations of, and compositions comprising, such cells. Further provided herein are methods of obtaining such cells and methods of using the cells in the treatment of individuals.

Claims

1. An isolated population of cells, wherein at least 50% of the cells in said population are human amnion derived adherent cells, wherein said amnion derived adherent cells are adherent to tissue culture plastic, and wherein said amnion derived adherent cells are OCT-4⁻

(octamer binding protein

     4) as determined by RT-PCR, and CD49f⁺, CD90⁺, and HLA-G⁻

as determined by flow cytometry.

2. The isolated population of cells of claim 1, wherein at least 90% of the cells in said population are amnion derived adherent cells.

3. A composition comprising the isolated population of cells of claim 1.

4. The isolated population of cells of claim 1, comprising a second type of cell, wherein said second type of cell is an embryonic stem cell, a blood cell, a stem cell isolated from peripheral blood, a stem cell isolated from placental blood, a stem cell isolated from placental perfusate, a stem cell isolated from placental tissue, a stem cell isolated from umbilical cord blood, an umbilical cord stem cell, a bone marrow-derived mesenchymal stem cell, a bone marrow-derived mesenchymal stromal cell, a hematopoietic stem cell, a somatic stem cell, a chondrocyte, a fibroblast, a muscle cells, an endothelial cell, an angioblast, an endothelial progenitor cell, a pericyte, a cardiomyocyte, a myocyte, a cardiomyoblast, a myoblast, or an embryonic stem cell.

5. The isolated population of cells of claim 4, wherein said second type of cell comprises at least 10% of cells in said population.

6. The isolated population of cells of claim 4, wherein said second type of cell comprises at least 25% of cells in said population.

7. The isolated population of cells of claim 4, wherein said second type of cell is a hematopoietic stem or progenitor cell.

8. The isolated population of cells of claim 7, wherein said hematopoietic stem or progenitor cell is a CD34⁺ cell.

9. The isolated population of cells of claim 1, wherein at least 70% of the cells in said population are amnion derived adherent cells.

10. The isolated population of cells of claim 1, wherein at least 80% of the cells in said population are amnion derived adherent cells.

11. The isolated population of cells of claim 1, wherein at least 95% of the cells in said population are amnion derived adherent cells.

12. The isolated population of cells of claim 1, wherein at least 99% of the cells in said population are amnion derived adherent cells.

13. The isolated population of cells of claim 4, wherein said second type of cell is a cardiomyocyte or a cardiomyoblast.

14. The isolated population of cells of claim 4, wherein said second type of cell is a chondrocyte, a muscle cell, an endothelial cell, an endothelial progenitor cell, or a myoblast.